Aimmune Therapeutics Shares Gain

Aimmune Therapeutics (AIMT) gained more than 6% after the company said findings from pre-randomization, preliminary clinical data collected from the European screening population of the PALISADE trial in Aimmune’s AR101 program showed 62% of patients enrolled were reactors who experienced dose-limiting symptoms in the double-blind, placebo-controlled food challenge (DBPCFC) at or before the 100-mg dose and 38% were “non-reactors” who consumed all doses in the DBPCFC with no dose-limiting symptoms.

Reactors had a statistically significant larger peanut skin-prick test (SPT) wheal diameters, a higher peanut-specific IgE (psIgE) and higher Ara h 2-specific IgE than non-reactors. Ara h 2-specific IgE demonstrated greatest sensitivity and specificity for discriminating between reactors and non-reactors, based on receiver operating characteristic (ROC) curve analysis of the data.

SPT, peanut-specific IgE and Ara h 2 were not associated with the severity of reactions during the screening DBPCFC. “The screening data from these patients that we have presented at EAACI provide an interesting insight into the characteristics of patients who are sensitive to very small amounts of peanut protein,” said Sue Barrowcliffe, general manager of Aimmune Europe.

By William Spence